Octobre 2012 - IMCAS Hong Kong, the top-shelf of science-approuved Asia aesthetic approaches

1.
IMCAS
PRESS
OFFICE
-­‐
P.B
Communication
7
Villa
des
Sablons–
92200
Neuilly
sur
Seine
-­‐
Tel
:
+
33
1
47
31
11
06
-­‐
E-­‐mail
:
pbcom@wanadoo.fr
www.imcas.com
IMCAS
ASIA
2
0
1
2
PRESS
KIT
THURSDAY,
October
4th
2012

2.
PRESS
Kit
–
Hong
Kong
-­‐
October
2012
IMCAS
PRESS
OFFICE
-­‐
P.B
Communication
7
Villa
des
Sablons–
92200
Neuilly
sur
Seine
-­‐
Tel
:
+
33
1
47
31
11
06
-­‐
E-­‐mail
:
pbcom@wanadoo.fr
www.imcas.com
2
IMCAS ASIA Returns to Hong Kong in 2012
October
4
to
6,
2012
Intercontinental
Hotel
Convention
Center
This
year,
for
its
6
th
Asian
edition,
IMCAS
is
glad
to
organize
its
very
first
IMCAS
Asian
Press
Conference,
where
all
media
and
journalists
worldwide
are
welcome.
About
IMCAS
IMCAS
is
one
of
the
most
important
European
Courses
dedicated
to
Plastic
Surgery
and
Cosmetic
Dermatology.
By
welcoming
more
than
3
500
delegates
each
year
during
its
annual
worldwide
conference
in
Paris,
it
represents
a
true
«medical
population
sampling».
Its
main
objective
is
to
promote
the
highest
possible
standards
in
clinical
practice,
education
and
research
within
the
plastic
surgery
/
dermatology
interface,
as
well
as
in
related
disciplines
(facial
plastic
surgery,
oculoplastic
surgery,
aesthetic
medicine,
research,
etc…).
It’s
now
an
institutional
teaching
congress,
working
with
advices
from
several
learned
societies
such
as
the
SOFCEP
(Société
Française
des
Chirurgiens
Esthéticiens
Plasticiens),
the
ESLD
(European
Society
for
Laser
Dermatology)
and
the
ASDS
(American
Society
for
Dermatologic
Surgery).
IMCAS
Industry
Tribune
Additionally,
IMCAS
is
also
strongly
identified
and
recognized
as
a
major
information
source
when
it
comes
to
the
economical
and
financial
aspects
of
this
segment.
The
IMCAS
Industry
Tribune,
gathering
each
year
the
major
players
of
the
economical
field
(representatives
from
the
most
relevant
companies,
financial
analysts,
medical
and
economical
journalists...),
is
indeed
the
leading
forum
in
analyzing
the
aesthetic
medical
market.
IMCAS
Asia
What’s hot in IMCAS Hong Kong 2012?
It’s
been
six
years
since
the
International
Master
Course
on
Aging
Skin
(IMCAS)
acknowledged
that
Asia
holds
a
big
part
of
the
future
of
aesthetic
surgery
and
medicine.
IMCAS
organized
the
very
first
Asian
conference
in
2007
in
Bangkok,
and
since
then
has
expanded
to
feature
three
Asian
editions
each
year:
IMCAS
China
(Shanghai;
July
28-­‐29),
IMCAS
Asia
(Hong
Kong,
October
4-­‐6),
IMCAS
Singapore,
July
26-­‐28,
2013
and
IMCAS
India
(Goa,
November
23-­‐24,
2013);
making
Asia
its
second
focus
of
action
to
continue
growing,
contributing
and
exchanging
knowledge
and
information
about
aesthetic
medicine
and
plastic
surgery
across
a
continent
known
best
for
its
development
and
innovation.
In
2012,
IMCAS
chose
to
reiterate
an
exciting
Hong
Kong’s
edition
for
the
2nd
time
as
this
city
appears
to
be
a
whole
world
itself,
and
one
of
the
top
medical
and
economical
players
on
the
globe.
IMCAS
is
very
tight
to
Hong
Kong
Scientific
Committee
and
IMCAS
Asia
is
a
congress
supported
by
not
less
than
3
Universitary
learned
societies:
The
Hong
Kong
College
of
Dermatologists
The
Hong
Kong
Society
of
Dermatology
and
Venereology
Hong
Kong
Society
of
Plastic,
Reconstructive
and
Aesthetic
Surgeons

3.
PRESS
Kit
–
Hong
Kong
-­‐
October
2012
IMCAS
PRESS
OFFICE
-­‐
P.B
Communication
7
Villa
des
Sablons–
92200
Neuilly
sur
Seine
-­‐
Tel
:
+
33
1
47
31
11
06
-­‐
E-­‐mail
:
pbcom@wanadoo.fr
www.imcas.com
3
With
the
participation
of
experts
known
and
recognized
in
Asia
and
well
as
all
over
the
world:
COURSE
COORDINATORS
CHAN
Henry
Hin
Lee,
Dermatologist,
HONG
KONG
WONG
David
Sau
Yan,
Plastic
Surgeon,
HONG
KONG
SCIENTIFIC
SECRETARIES
GOH
Chee
Leok,
Dermatologist,
SINGAPORE
HO
Henry
Hing
Fung,
Dermatologist,
HONG
KONG
ZAKINE
Gilbert,
Plastic
Surgeon,
FRANCE
COURSE
DIRECTOR
ASCHER
Benjamin,
Plastic
Surgeon,
FRANCE
However
IMCAS
always
sought
to
cover
the
whole
Pacific
Asia
territory,
thus
explores
different
countries
(Thailand,
Singapore,
Korea,
Japan...)
and
has
launched
a
brand
new
congress
past
July
,
the
very
first
IMCAS
China,
which
was
a
huge
success
beyond
our
expectations.
A
rich
and
affluent
attendance
has
been
noticed,
considering
IMCAS
China
2012
was
a
first
and
managed
to
attract
1
200
attendees.
In
the
end,
IMCAS
was
able
to
put
on
the
international
stage
the
new
blood
from
China,
and
was
very
happy
and
proud
to
bring
the
best
of
foreign
speakers,
whether
European,
American
or
Asian,
in
China.
IMCAS
Hong
Kong
It's
the
same
goal
we
wish
to
reach
here,
as
we
did
for
each
Asian
edition
of
IMCAS
Congresses:
allowing
exchange
between
experts
from
all
over
the
globe,
with
a
major
focus
on
Asian
practice
of
plastic
surgery
and
cosmetic
dermatology.
The
IMCAS
HKG
Scientific
Board
and
Committee,
with
a
consequent
list
of
international
faculty
speakers,
has
built
a
challenging
program,
spread
over
4
simultaneous
rooms,
each
dedicated
to
scientific
contents
and
formats:
aesthetic
surgery,
cosmetic
dermatology
and
interface,
live
demos
and
under
full
disclosure,
satellite
symposia
from
the
exhibiting
companies.
Covering
all
the
major
topics
and
trends,
IMCAS
HKG
program
has
been
developed
around
diverse
threads,
with
a
narrative
and
logical
evolution,
from
pathology
to
aesthetic.
Staying
true
to
its
spirit
of
exchange,
IMCAS
intends
to
consolidate
the
aesthetic
fundamentals
while
beneficiating
from
the
expertise
and
specialities
of
HKG’s
leading
speakers
and
practitioners
That's
why
we
are
proud
to
organize
today
this
press
conference
with
the
greatest
practitioners
of
Hong
Kong:
Dr.
Henry
Chan,
Dr.
Stephanie
Lam
and
Dr.
George
Li,
as
well
as
speakers
from
all
Asia
(Singapore,
Japan)
and
western
experts
Dr.
Zakine…,Dr.
Illouz,
the
father
of
the
liposuccion
technique.
This
press
conference
will
open
with
a
focus
on
the
market
figures
–
for
IMCAS
is
also
known
as
a
primary
information
source
when
it
comes
to
the
aesthetic
market
Intel.
The
IMCAS
INDUSTRY
TRIBUNE,
our
economic
forum,
will
follow
the
press
conference,
inviting
any
interested
journalist
to
attend
a
2-­‐hour
session
featuring
key
economic
actors
of
the
market
for
round
tables
et
debates.
Welcome
to
the
first
IMCAS
Asia
Press
Conference.
Benjamin
Ascher,MD,
Plastic
Surgeon,
FRANCE
IMCAS
Scientific
Director
SCIENTIFIC
COMMITTEE
(updated
list
on
www.imcas.com)
CASSUTO
Daniel,
Plastic
Surgeon,
ITALY
ILLOUZ
Yves
Gerard,
Plastic
Surgeon,
FRANCE
LI
George
Kam
Hop,
Plastic
Surgeon,
HONG
KONG
MANUSKIATTI
Woraphong,
Dermatologist,
THAILAND
MOLE
Bernard,
Plastic
Surgeon,
FRANCE
MU
David
Xiongzheng,
Plastic
Surgeon,
CHINA
OMI
Tokuya,
Dermatologist,
JAPAN

4.
PRESS
Kit
–
Hong
Kong
-­‐
October
2012
IMCAS
PRESS
OFFICE
-­‐
P.B
Communication
7
Villa
des
Sablons–
92200
Neuilly
sur
Seine
-­‐
Tel
:
+
33
1
47
31
11
06
-­‐
E-­‐mail
:
pbcom@wanadoo.fr
www.imcas.com
4
IMCAS
HONG
KONG
The
top-­‐shelf
of
science-­‐approved
Asia
aesthetic
approaches
Aesthetics
is
foremost
medicine,
a
discipline
of
its
own,
but
often
clouded
by
non-­‐scientific
works
and
reports
which
drive
the
segment
offshores.
As
of
today,
it's
not
always
easy
to
know
who
you're
talking
to.
Doctor,
non
doctor?
That's
why
it's
essential
to
make
sure
that
each
treatment;
intervention
or
technology
is
scientifically
validated
and
clinically
proven
to
work
towards
the
risk
0.
Thus
IMCAS
will
present,
analyze
and
discuss
new
treatments,
secure
procedures
and
tomorrow's
technologies
with
experts
known
and
recognized
in
Asia
and
around
the
world.
Asian
beauty
has
its
own
standards
and
therefore
its
specific
aesthetic
approaches
The
main
goal
of
IMCAS
is
thus
to
ensure
medical
and
scientific
validation
SUMMARY
INTRODUCTION
• IMCAS:
where
are
we?
Why
IMCAS
ASIA
in
Hong
Kong?
ASCHER
Benjamin,
IMCAS
Asia
Course
Director
• IMCAS
ASIA
Industry
Tribune:
the
largest
observatory
of
the
ASIA
aesthetic
market
The
Asian
aesthetic
market:
structure,
features
and
trends
taking
into
account
the
consequences
of
the
current
financial
environment
Laurent
BRONES,
Business
Development
Manager,
SYMATESE,
France
IMCAS
Tribune
Coordinator
Why the non-surgical approach is so popular in Asia?
Face
and
body
treatments
-­‐
what’s
new?
-­‐
Science
to
support!
Body
countouring:
the
recent
advances
of
cosmetic
dermatology
• IR,
RF,
IPL,
YAG
&
tightening
and
other
alternatives
energy
devices:
does
it
really
work?
What
results
can
be
expected?
…
Up
and
downsides?
CHAN
Henry
Hin
Lee,
Dermatologist,
HONG
KONG
Redraw
the
shape
of
the
face
with
injectables
• How
to
treat
upper,
mid
and
lowerface
volume?
• Hyaluronic
Acid:
lift,
volumize,
block
LAM
Stephanie
Chuk
Kwan,
Plastic
Surgeon,
HONG
KONG
New
trends
in
Cellulite
and
body
shaping
• Injectables,
InfraRed,
Ultrasound,
Lasers
Radiofrequency,
Roller:
Indications
&
cons-­‐indications
DUCAN
Diane
Irvine,
Plastic
Surgeon,
USA
Asian
Toxin
treatment
• Product
overview
• New
trends
and
future
of
Botulinum
Toxins
ASCHER
Benjamin,
Plastic
Surgeon,
FRANCE
The
fake
market
in
fillers
and
Toxins
• The
dangers
of
counterfeiting
in
fillers
and
toxins
• How
to
recognize
the
certified
product?
PICKETT
Andy,
PhD
Research,
UNITED
KINGDOM
Toxin
Science
Limited

5.
PRESS
Kit
–
Hong
Kong
-­‐
October
2012
IMCAS
PRESS
OFFICE
-­‐
P.B
Communication
7
Villa
des
Sablons–
92200
Neuilly
sur
Seine
-­‐
Tel
:
+
33
1
47
31
11
06
-­‐
E-­‐mail
:
pbcom@wanadoo.fr
www.imcas.com
5
Face and body procedures: what’s hot?
Orbital
reshapping
-­‐ Combined
treatments
PENG
Peter,
Dermatologist,
TAIWAN
Eyelids
and
“regard”
-­‐ Eyelid
and
surgical
Asian
approach:
what’s
hot?
LO
Stephen,
Facial
Plastic
Surgeon,
SINGAPORE
Refine
her
nose:
-­‐ Asian
rhinoplasty:
Medical
versus
surgical
ZAKINE
Gilbert,
Plastic
Surgeon,
FRANCE
Commentary:
LO
Stephen,
Facial
Plastic
Surgeon,
SINGAPORE
Safety
in
breast
implants
–
What's
hot
in
Hong
Kong?
LAM
Stephanie
Chuk
Kwan,
Plastic
Surgeon,
HONG
KONG
Update
on
stem
cells
&
lipofilling
–
Face,
breast
&
body:
the
Regenerative
Medecine
ILLOUZ
Yves
Gérard,
Plastic
Surgeon,
FRANCE

6.
PRESS
Kit
–
Hong
Kong
-­‐
October
2012
IMCAS
PRESS
OFFICE
-­‐
P.B
Communication
7
Villa
des
Sablons–
92200
Neuilly
sur
Seine
-­‐
Tel
:
+
33
1
47
31
11
06
-­‐
E-­‐mail
:
pbcom@wanadoo.fr
www.imcas.com
6
IMCAS ASIA HONG KONG INDUSTRY TRIBUNE
Thursday
October
4th
-­‐
2012,
from
4.30
PM
to
6
PM
ROOM
4
Medical
and
surgical
aesthetic
market,
2010
–
2016
Laurent
BRONES,
Business
Development
Manager,
SYMATESE,
France
IMCAS
Tribune
Coordinator
The
Tribune
IMCAS
2012
combines
the
data
available
on
the
medical
&
surgical
aesthetic
market,
supplied
by
the
Market
Studies
Societies
(MRG
&
MII
NEWS),
the
financial
analysts
and
the
industrial
executives
attending
the
2012
Tribune,
including
Allergan,
Galderma,
Skinceuticals,
Syneron,
as
well
as
the
data
from
the
ISAPS
(International
Society
of
Aesthetic
and
Plastic
Surgery)
Study
on
the
different
procedures
practiced
over
2010.
The
IMCAS
Tribune
thus
realised
an
exhaustive
and
unseen
analysis
on
the
different
territories
(Europe,
USA,
Pacific
Asia,
Latin
America)
between
2010
and
2016,
in
US$,
covering
the
most
important
segments
of
the
market:
botulinum
toxins,
fillers,
active
cosmetics,
lasers
and
energy
devices,
breast
implants.
The
variations
here
observed
between
the
different
information
sources
available
bring
us
to
make
an
evaluation
of
the
different
market
segments
on
two
hypothesis:
one
high,
one
low.
Market
facts
and
key
figures
The
world
market
1
is
evaluated
between
4,3
and
5,1
Billions
US
$
for
2011,
i.e.
+
10,1%
compared
to
2010,
with
an
expected
growth
of
+11,2%
in
2012,
being
thus
a
demonstration
of
the
sector's
dynamic
state.
Asia
will
experience
the
stronger
growth
up
until
2016,
and
will
reach
the
European
market
standards
to
1,49
–
1,79
Billions
US$
with
an
average
annual
growth
of
15,7%,
against
7%
only
for
Europe.
The
United
States
and
Latin
America
will
know
a
annual
rate
of
about
11%.
The
North
America
market
will
still
represent
45%
of
the
global
market.
The
European
financial
debt
and
crisis
should
impact
the
European
Market
in
2012,
with
a
growth
estimated
up
to
+5%
between
2012
and
2011.
According
to
our
high
and
low
estimations,
the
European
market
should
be
in
the
range
of
1,04
–
1,27
Millions
US$
to
grow
in
2012
to
1,46
–
1,78
Millions
US
$.
The
annual
growth
of
the
market
between
2012
and
2016
should
be
of
11,2%,
reaching
7,3
to
8,6
Billions
US$.
Procedures
per
area
1
Including
the
sales
activities
from
practitioners,
users
and
distributors

7.
PRESS
Kit
–
Hong
Kong
-­‐
October
2012
IMCAS
PRESS
OFFICE
-­‐
P.B
Communication
7
Villa
des
Sablons–
92200
Neuilly
sur
Seine
-­‐
Tel
:
+
33
1
47
31
11
06
-­‐
E-­‐mail
:
pbcom@wanadoo.fr
www.imcas.com
7
Regarding
the
different
market
segments,
the
injectable
products
(toxins
and
fillers)
are
still
the
first
market
segment
in
value,
and
will
keep
on
growing
for
an
average
of
+10%
per
year
through
2016,
confirming
their
development
potential
for
many
years.
The
energy-­‐based
devices
(laser,
radiofrequency,
ultrasounds)
will
catch
up
with
the
decrease
in
business
due
to
2008-­‐2009
financial
crisis,
with
a
average
annual
growth
of
13,2%
through
2016.
The
cosmeceutics
(active
cosmetics),
new
market
segment
analysed
within
the
Tribune
2012,
will
follow
the
same
trends
than
the
injectable
products.
The
breast
implants
will
experience
a
reduced
progression,
estimated
to
5,7%
through
2016,
fitting
the
progressions
observed
those
last
years.
Possibly
subjected
to
an
impact
of
the
PIP
affair,
the
market
could
evolve
in
a
less
favourable
way,
especially
in
Europe.
The
market
segments
are,
sorted
out
by
decreasing
order
of
importance,
are
the
following
ones:
(area
sorted
out
by
decreasing
order)
1. Injectable
products
(Toxins
and
fillers)
a. From
1,65-­‐1,99
Billions
US$
in
2011,
projected
to
2,75-­‐3,32
Billions
US$
to
2016
b. Average
annual
growth
2011-­‐2016:
+11,1%
c. Main
areas:
USA,
EU,
Asia,
South
America.
2. Energy
based
devices
a. From
1,13-­‐1,32
Billions
US$
in
2011,
projected
to
2,2-­‐2,58
Billions
US$
for
2016
b. Average
annual
growth
2011-­‐2016:
+13,2%
c. Main
areas:
USA,
EU
and
Asia
2
,
South
America.
3. Breast
prosthetic
implants:
a. From
860-­‐1045
Millions
US$
in
2011,
projected
to
1,15-­‐1,4
Billions
US$
for
2016
b. Average
annual
growth
2011-­‐2016:
+5,7%
c. Main
areas:
USA,
Latin
America,
EU,
Asia.
4. Cosmeceutics
(active
cosmetic)
a.
From
695-­‐765
Millions
US$
in
2011,
projected
to
1,2-­‐1,31
Billions
US$
for
2016,
b. Average
annual
growth
2011-­‐2016:
+11,1%
c. Main
areas:
USA,
Asia,
Latin
America,
EU.
Surgical
interventions
and
non-­‐invasive
procedures:
the
top
5
According
to
ISAPS
data,
the
USA,
Latin
America,
Europe
and
Asia
represents
respectively
24,6%,
19,6%,
21,4%
and
31,7%
of
the
surgical
interventions
practiced
worldwide,
thus
revealing
the
success
of
plastic
surgery
in
India
and
China.
WORLDWIDE,
the
surgical
interventions
the
most
practiced
are,
here
sorted
out
by
decreasing
order
(countries
sorted
by
decreasing
order):
1. Liposuction:
Brazil,
USA,
China,
India,
Japan
2. Breast
augmentation
USA,
Brazil,
Mexico,
Italy
China
3. Blepharoplasty
(eyelids):
Brazil,
USA,
China,
India,
Japan,
Italy
4. Rhinoplasty:
Brazil,
USA,
China,
Japan,
India
5. Abdominoplasty
(tummy
tuck):
USA,
Brazil,
Mexico,
India,
China
2
The
equipment
market
in
Asia
should
overtake
the
European
market
in
2016

8.
PRESS
Kit
–
Hong
Kong
-­‐
October
2012
IMCAS
PRESS
OFFICE
-­‐
P.B
Communication
7
Villa
des
Sablons–
92200
Neuilly
sur
Seine
-­‐
Tel
:
+
33
1
47
31
11
06
-­‐
E-­‐mail
:
pbcom@wanadoo.fr
www.imcas.com
8
WORLDWIDE,
the
non-­‐invasive
procedures
the
most
practiced
are,
here
sorted
out
by
decreasing
order
(countries
sorted
by
decreasing
order):
1. Botulinum
toxin:
USA,
Brazil,
China,
Japan,
Mexico
2. Hyaluronic
acid:
USA,
China,
Japan,
Italy,
Brazil,
3. Lipofilling:
Brazil,
USA,
China,
Japan,
India
4. Laser
hair
removal:
USA,
Brazil,
China,
Japan,
India
5. IPL
Laser
treatment:
USA,
Brazil,
Japan,
China,
India
In
ASIA,
the
surgical
interventions
the
most
practiced
are,
here
sorted
out
by
decreasing
order
(countries
sorted
by
decreasing
order):
1. Liposuction:
China,
India,
Japan,
South
Korea,
Taiwan
2. Rhinoplasty:
China,
Japan,
India,
South
Korea,
Taiwan
3. Blepharoplasty:
China,
Japan,
India,
South
Korea,
Taiwan
4. Breast
augmentation:
China,
India,
Japan,
South
Korea,
Taiwan
5. Abdominoplasty:
India,
China,
Japan,
South
Korea,
Taiwan

9.
PRESS
Kit
–
Hong
Kong
-­‐
October
2012
IMCAS
PRESS
OFFICE
-­‐
P.B
Communication
7
Villa
des
Sablons–
92200
Neuilly
sur
Seine
-­‐
Tel
:
+
33
1
47
31
11
06
-­‐
E-­‐mail
:
pbcom@wanadoo.fr
www.imcas.com
9
In
ASIA,
the
non-­‐invasive
procedures
(only
plastic
surgeons)
the
most
practiced
are,
here
sorted
out
by
decreasing
order
(countries
sorted
by
decreasing
order):
1. Botulinum
toxin:
China,
Japan,
India,
South
Korea,
Taiwan
2. Hyaluronic
acid:
China,
Japan,
India,
South
Korea,
Taiwan
3. Lipofilling:
China,
Japan,
India,
South
Korea,
Taiwan
4. Laser
hair
removal:
China,
Japan,
India,
South
Korea,
Taiwan
5. IPL
Laser
treatment:China,
Japan,
India,
South
Korea,
Taiwan

10.
PRESS
Kit
–
Hong
Kong
-­‐
October
2012
IMCAS
PRESS
OFFICE
-­‐
P.B
Communication
7
Villa
des
Sablons–
92200
Neuilly
sur
Seine
-­‐
Tel
:
+
33
1
47
31
11
06
-­‐
E-­‐mail
:
pbcom@wanadoo.fr
www.imcas.com
10
Why the non-surgical approach is so popular in Asia?
Face
and
body
treatments
-­‐
what’s
new?
-­‐
Science
to
support!
Body countouring: the recent advances of cosmetic dermatology
IR,
RF,
IPL,
YAG
&
tightening
and
other
alternatives
energy
devices:
does
it
really
work?
What
results
can
be
expected?
…
Up
and
downsides?
CHAN
Henry
Hin
Lee,
Dermatologist,
HONG
KONG
Skin
laxity
is
one
of
the
most
common
compliant
in
cosmetic
practice
and
while
surgical
procedures
such
as
face
lift
remains
to
be
the
gold
standard,
non-­‐invasive
procedures
have
gained
much
popularity
due
to
lack
of
down
time
and
much
lower
risk
of
complication.
This
talk
will
review
the
use
of
laser,
light
source,
focused
ultrasound
and
radiofrequency
that
have
been
used
for
skin
tightening.
The
principle
of
skin
tightening
using
medical
devices
involve
deep
tissue
heating
whereby
energy
is
delivered
to
the
deep
dermis
causing
collagen
damage,
subsequently
healing
process
leads
to
new
collagen
formation
and
skin
tightening
effect.
For
medical
devices,
it
can
be
achieved
in
three
manners,
non-­‐invasive,
semi-­‐invasive
and
minimal
invasive.
Redraw the shape of the face with injectables
How
to
treat
upper,
mid
and
lowerface
volume?
Hyaluronic
Acid:
lift,
volumize,
block.
LAM
Stephanie
Chuk
Kwan,
Plastic
Surgeon,
HONG
KONG
Asian
faces
are
often
square
or
round
in
shape.
Using
injectables
such
as
Botulinum
toxin
and
various
types
of
fillers,
we
can
redraw
the
shape
of
the
face
so
that
they
are
closer
to
the
perceived
ideal
oval
shape.
Injectables
treatments
are
effective,
safe
and
can
be
tailored
to
individual
needs.
Especially
in
the
use
of
fillers,
the
procedure
can
be
gradual
and
interactive
so
that
the
patient
can
help
decide
on
their
final
appearance.
In
experienced
hands,
the
results
can
be
natural,
subtle
yet
dramatic,
improving
their
looks
as
well
as
their
self
esteem.
New trends in cellulitis and body shaping
DUNCAN
Diane,
Plastic
Surgeon,
USA
A
new
understanding
of
the
physiology
of
cellulite
formation
has
lead
to
the
development
of
new
and
better
tools
to
treat
the
problem,
with
long
term
results.
Cellulaze
was
recently
given
FDA
clearance
for
treatment
of
cellulite-­‐-­‐not
the
usual
"temporary"
category.
The
device
releases
the
retaining
tissue
that
causes
the
visible
depressions.
Another
totally
non-­‐invasive
device
gives
excellent
results
with
cellulite
using
a
combination
of
radiofrequency
energy
plus
vacuum.
The
RF
heat
tightens
the
loose
fibrous
connections,
correcting
tissue
laxity.
The
vacuum
aspect
of
the
Reaction
device
releases
the
tight
fibbers,
helping
to
even
out
the
irregular
surface.
Both
devices
cause
some
fat
reduction.
In
cases
of
true
cellulite,
liposuction
is
rarely
used
any
more
as
it
tends
to
worsen
the
surface
irregularity.
An
ideal
solution
for
localized
fat
would
be
"melting"
without
any
needles,
surgery,
swelling,
or
other
recovery
issues.
The
Tite
FX
is
also
RF
based.
It
utilizes
heat,
vacuum,
plus
a
boost
of
RF
energy
to
reduce
fat
without
any
external
signs
of
treatment.
Our
current
DA
study
shows
an
average
of
47%
reduction
of
fat
thickness
with
8
treatments
performed
over
an
8-­‐week
period.
As
technology
improves,
patient
demands
for
better
results
with
less
scarring
and
downtime
increase.
Tissue
tightening
can
be
created
with
energy
assisted
liposuction
instead
of
resorting
to
cutting
out
skin.
Even
scarless
breast
lifting
has
been
able
to
achieve
long
term
results
lasting
a
year
or
more,
using
energy
assisted
tissue
tightening.

11.
PRESS
Kit
–
Hong
Kong
-­‐
October
2012
IMCAS
PRESS
OFFICE
-­‐
P.B
Communication
7
Villa
des
Sablons–
92200
Neuilly
sur
Seine
-­‐
Tel
:
+
33
1
47
31
11
06
-­‐
E-­‐mail
:
pbcom@wanadoo.fr
www.imcas.com
11
Asian Toxin treatment
Product
overview
New
trends
and
future
of
Botulinum
Toxins
ASCHER
Benjamin,
Plastic
Surgeon,
FRANCE
BACKGROUND:
Botulinum
neurotoxin
type
A
(BoNT-­‐A)[1,2]
is
a
simple,
safe,
and
very
effective
treatment
of
the
aging
face,
which
acts
through
transitory
and
reversible
minimal
palsies
of
target
muscles.
Botulinum
toxin
type
A
reduces
wrinkles,
changes
the
shape
and
position
of
important
facial
structures,
such
as
eyebrows,
delaying
or
avoiding
the
need
for
invasive
surgical
interventions
[3,4,5].
It
can
be
combined
with
other
invasive
and/or
minimally
invasive
procedures
such
as
fillers
and
lasers,
for
better
cosmetic
[5]
and
natural
results
in
order
to
improve
beauty,
with
no
distortions
and
keeping
facial
expression.
INJECTABLES
PRODUCTS,
with
a
focus
on
the
Asian
market:
The
most
widely
known
BT-­‐A
are
Botox/Vistabel®
(Allergan,
Inc,
Irvine,
USA)
and
Dysport/Azzalure®
(Ipsen
Ltd,
Maidenhead,
UK).
Following
a
huge
series
of
well-­‐referenced
published
papers,
from
both
pathological
as
well
as
cosmetic
indications,
clinical
conversion
tables
have
been
drawn
up
between
the
2
first
drugs:
1
unit
of
the
Allergan
product
is
approximately
equivalent
to
2,5
units
of
the
Ipsen/
Galderma
product
[
3,
4
,5,6
].
Both
are
registered
in
many
Asian
countries.
In
China
Botox
is
registered
for
glabellar
lines
since
2011.
Other
toxins
currently
existing
on
the
US
and
EU
market,
such
as
Xeomin/Bocouture®
(Merz
Pharmaceuticals,
Frankfurt,
Germany)
seem
to
have
around
a
1:1
dose
ratio
compared
with
Botox.
An
other
commercial
preparation,
PurTox®
(Mentor/J
and
J
Corporation,
Santa
Barbara,
USA)
with
completed
Phases
III,
has
not
been
yet
approved
by
the
FDA
territories.
The
BTX-­‐
B
Neurobloc
from
Ellan
laboratory
seems
to
be
less
effective
in
term
of
efficacy
durability,
and
with
some
additional
side
effects.
Although
it
was
supposed
to
be
dropped
for
the
cosmetic
indications,
it
seems
to
be
available
in
certain
Asian
countries
like
Korea,
and
new
US
trials
are
in
process.
The
Korean
Toxin,
Neuronox
from
Medy-­‐Tox,
is
approved
in
aesthetics
in
Mexico,
Brazil,
and
many
Asian
countries
as
well
as
the
Korean
Toxin
Botulax
from
Hugel
approved
in
Korean,
Japan
and
other
Asian
countries.
Meditox
launched
in
2006,
trough
the
approval
KFDA,
is
approved
for
Glabellar
lines
since,
2011
and
seems
to
have
a
formulation
clothed
to
1:1
dose
ratio
compared
with
Botox.
It
is
registered
in
24
countries,
like
Asia
Thailand,
Japan
and
under
many
names
:
Siax,
Botulift,
Cunox
as
well
as
in
India
&
China
through
the
Ranbaxy
distribution
and
under
the
name
of
Botulift
through
the
Amgen
distribution.
The
Chinese
Prosigne®,
BTXA
(from
Lanzhou
Institute
of
Biological
Products,
Lanzhou,
China)
is
approved
in
China
since
May
2012
and
distribute
in
several
Asian
and
Latin
American
countries.
Some
comparatives
studies
with
Botox,
mainly
in
neurology
seems
to
promote
a
dose
equivalence
of
1:1
for
both
products.
[
7
]
All
these
Korean
and
Chinese
toxins
have
not
yet
been
submitted
to
the
US
and
European
commissions
of
approval
with
referenced
published
papers,
in
the
purpose
to
be
ordered
in
the
EU
and
US
countries.

12.
PRESS
Kit
–
Hong
Kong
-­‐
October
2012
IMCAS
PRESS
OFFICE
-­‐
P.B
Communication
7
Villa
des
Sablons–
92200
Neuilly
sur
Seine
-­‐
Tel
:
+
33
1
47
31
11
06
-­‐
E-­‐mail
:
pbcom@wanadoo.fr
www.imcas.com
12
OTHERS
PRODUCTS,
TECHNIQUES
and
DEVICES:
•
The
novel
topical
BT-­‐A,
RT001
(Revance
Therapeutics,
Newark,
USA),
from
the
nanotechnology
field
[8,9,10]
allow
the
toxin
to
cross
the
skin
barrier.
Early
results
appear
promising
for
the
treatment
of
primary
axillary
hyperhidrosis
and
lines,
however
the
product
is
still
in
phase
II
in
USA
and
we
don’t
know
when
phase
III
will
allow
distribution.
•
Hyaluronic
acid
filler
and
Botulinum
neurotoxin
can
be
prepared
in
extamporane
and
delivered
simultaneously
in
the
same
syringe.
This
technique
may
optimize
the
use
of
fillers
and
neurotoxins
for
some
areas
of
the
face,
such
as
crow’s
feet,
glabella
and
DAO/
pre
jowl
areas.
However,
limitation
of
smiling
could
occur
during
few
days.
•
Cold
induced
neuro-­‐modulation
using
a
minimally
invasive
Cryoprobe,
from
Myoscience
(California,
USA)
(10)
produce
immediate
dynamic
line
reductions
after
2-­‐8
Cryoprobe
insertions
near
the
motor
nerves.
Preliminary
results
suggest
a
“BTX-­‐A
like”
result
for
forehead
lines,
however
more
studies
with
refined
device
planned
are
required.
[11]
CONCLUSION:
Is
the
future
lie
with
the
standard
Botulinum
toxin
injection?
What
will
be
the
future
of
new
products
available,
of
new
formulation
of
the
classical
products,
of
nanotechnologies,
of
alternative
system
of
neuromodulation,
new
combined
treatments?
We
don't
know
yet;
however
we
do
know
the
potential
of
development
of
these
segment:
12%
of
growing
per
year
until
2014
on
the
world
market,
and
15%
in
Asia.
The
injectable
toxins
are
still
one
of
the
major
cosmetic
medical
treatments.
The
rules
of
thumb
for
a
safe
injection
are
the
following:
know
deeply
facial
anatomy
as
well
as
each
product
characteristic,
make
a
careful
selection
of
injection
points,
adapt
the
depth
of
injection
depending
on
the
muscle
anatomy,
physiology
&
muscle
mass,
use
low
injection
volume,
and
use
lowest
effective
dose
per
point
to
obtain
a
natural
look
with
a
good
balance
between
efficacy
and
safety.
REFERENCES
1.
Carruthers
J,
Carruthers
A.
Botulinum
toxin
in
facial
rejuvenation:
an
update.
Dermatol
Clin
2009:27(4):417-­‐25;
2.
Brandt
F,
Swanson
N,
Baumann
L,
Huber
B.
Randomized,
placebo-­‐controlled
study
of
a
new
botulinum
toxin
type
a
for
treatment
of
glabellar
lines:
efficacy
and
safety.
Dermatol
Surg
2009:35(12):1893–1901.
3.
.
Ascher
B,
Talarico
S,
Cassuto
D,
et
al.
International
consensus
recommendations
on
the
aesthetic
usage
of
botulinum
toxin
type
A
(Speywood
Unit)
–
part
I:
upper
facial
wrinkles.
JEADV
2010;
24(11):
1278-­‐1284.
4
.Ascher
B,
Talarico
S,
Cassuto
D,
Escobar
S,
Hexsel
D,
Jaén
P,
Monheit
GD,
Rzany
B,
Viel
M.
International
consensus
recommendations
on
the
aesthetic
usage
of
botulinum
toxin
type
A
(Speywood
Unit)
–
part
II:
wrinkles
on
the
middle
and
lower
face,
neck
and
chest.
JEADV
2010;
24(11):
1285-­‐1295.
5.
Ascher
B,
Landau
M,
Rossi
B.
Injection
treatments
in
cosmetic
surgery.
Informa
Healthcare,
London.
Editor
2008
6.
Rzany
B.,
Ascher
B.
&
Monheit
G.
Treatment
of
glabellar
lines
with
botulinum
toxin
type
A
(Speywood
unit)
–
A
clinical
overview.
JEADV
2010,
24
(Suppl.
1):
1-­‐14.
7.
WU
Y.
chinese
clinic
studies
overview,
IMCAS
Shanghai
July
2012,
Abstract
8.
Collins
A,
Nasir
A.
Topical
botulinum
toxin.
J
Clin
Aesthet
Dermatol
2010;3(3):35-­‐9.
9.
Brandt
F,
O'Connell
C,
Cazzaniga
A,
Waugh
JM.
Efficacy
and
safety
evaluation
of
a
novel
botulinum
toxin
topical
gel
for
the
treatment
of
moderate
to
severe
lateral
canthal
lines.
Dermatol
Surg
2010;36
Suppl
4:2111-­‐8.
10.
Glogau,
et
al,
Journal
of
Drugs
in
Dermatology,
Volume
11,
Issue
1,
January
2012
11.
Cold-­‐Induced
Modulation
of
Targeted
Facial
nerves:
A
Unique
Procedure
to
Reduce
Dynamic
Forehead
Lines
Without
the
Use
of
Neurotoxins”,
Francis
Palmer
&
All,
2011
IMCAS
JAN
abstract.

13.
PRESS
Kit
–
Hong
Kong
-­‐
October
2012
IMCAS
PRESS
OFFICE
-­‐
P.B
Communication
7
Villa
des
Sablons–
92200
Neuilly
sur
Seine
-­‐
Tel
:
+
33
1
47
31
11
06
-­‐
E-­‐mail
:
pbcom@wanadoo.fr
www.imcas.com
13
The Fake Market in Fillers and Toxins
Andy
Pickett
Director
and
Founder,
Toxin
Science
Limited,
Wrexham
UK
Adjunct
Professor,
Center
for
Botulinum
Research,
UMASS
Dartmouth,
USA
Head
of
Development,
Q-­‐Med
(a
Galderma
Division),
Uppsala,
Sweden
As
the
demand
for
non-­‐surgical
facial
aesthetic
treatments
increases
around
the
world,
there
is
also
a
demand
for
low-­‐cost
products.
This
demand
arises
from
various
groups,
but
mostly
from
patients
-­‐
who
want
to
self-­‐administer
these
products
at
home
-­‐
and
a
few
practitioners,
who
just
want
to
use
the
cheapest
available
products.
Fortunately,
this
last
group
is
very
small
and
mainly
restricted
to
illegal
clinics
and
beauty
centres.
With
this
demand,
we
have
seen
an
ongoing
supply
of
these
fake
products
from
the
Internet,
readily
available
and
colourful,
attractive
to
people
by
interesting
names
which
claim
their
benefit
–
Excellent,
Amazing,
Fine
-­‐
or
even
“technically”
sounding
–
Syneurox,
Refinex.
Others
of
course
like
to
copy
directly
the
original,
authentic
product
by
counterfeiting
the
product
or
giving
similar
names,
often
confusing
to
the
buyer.
Whether
dermal
filler
or
botulinum
toxin
(BoNT),
the
situation
is
the
same.
The
same
name
can
also
be
given
to
either
a
BoNT
product
or
a
dermal
filler.
This
is
exceptionally
dangerous
as
BoNT
is
used
in
minute
quantities
and
the
dermal
filler
in
much
larger
quantities,
to
achieve
the
desired
effects.
One
is
an
active
blocker
of
muscle
active,
a
muscle
relaxant,
the
other
an
inactive
material
very
similar
to
material
naturally
found
in
the
skin.
They
are
completely
different.
Added
to
all
this,
the
ready
availability
of
videos
on-­‐line
showing
patients
how
and
where
to
inject
themselves
in
the
face
is
extraordinary.
One
Internet
supplier
even
sends
a
copy
of
a
DVD
with
their
instructions!
Dermal
fillers
and
BoNT
products
have
been
available
for
many
years
from
highly
reputable
companies,
licensed
and
regulated
by
the
countries
where
they
commercialise
the
products
in
accordance
with
standards
established
to
protect
and
safeguard
patients.
The
quality
of
these
products
is
exceptional.
They
are
supported
by
clinical
data
looking
at
both
safety
and
efficacy
of
the
products
in
different
applications.
In
areas
such
as
the
face,
they
are
tested
to
the
highest
standards.
These
products
are
only
available
through
recognised
and
established
supply
chains
that
guarantee
product
quality
at
all
times.
The
cheap
products
are
not
comparable
to
the
genuine,
branded
products.
They
should
never
be
compared.
Perhaps
more
important
than
anything
else,
there
is
no
assurance
that
they
are
sterile,
risking
infection
of
the
patient
if
used.
The
products
will
be
discussed
and
the
issues
considered,
with
examples
of
fake
products
commonly
available.

14.
PRESS
Kit
–
Hong
Kong
-­‐
October
2012
IMCAS
PRESS
OFFICE
-­‐
P.B
Communication
7
Villa
des
Sablons–
92200
Neuilly
sur
Seine
-­‐
Tel
:
+
33
1
47
31
11
06
-­‐
E-­‐mail
:
pbcom@wanadoo.fr
www.imcas.com
14
Face and body procedures: what’s hot?
Eyelids and “regard”
Eyelid
and
surgical
Asian
approach:
what’s
hot?
LO
Stephen,
Facial
Plastic
Surgeon,
SINGAPORE
Through
Asian
double
eyelid
surgery,
many
patients
wish
to
refashion
their
upper
eyelids
whilst
preserving
their
ethnic
identities.
In
the
past,
makeup
artists,
cosmetic
and
plastic
surgeons
produce
a
crease
that
is
placed
too
high
based
on
Caucasian
measurements,
assuming
that
patients
wish
to
have
a
westernised
eye.
Today,
this
misconception
is
avoided
by
employing
measurements
suited
for
the
Asian
eyes.
In
addition,
new
concepts
of
fat
preservation,
permanent
lid
crease
avoidance,
periorbital
rejuvenation,
and
ancillary
procedures
have
been
developed
all
aimed
to
achieve
a
more
natural
looking
and
aesthetic
pleasing
Asian
eyelid.
Refine her nose
Asian
rhinoplasty:
Medical
versus
surgical
ZAKINE
Gilbert,
Plastic
Surgeon,
FRANCE
Commentary:
LO
Stephen,
Facial
Plastic
Surgeon,
SINGAPORE
A
too
large
and
thick
nose
is
a
frequent
complains
of
the
patients
which
desire
a
rhinoplasty.
Thinning
the
nose
involved
all
the
part
of
the
nose
with
generally
osteotomies.
Nose
anatomy,
precise
patient
demand
and
anthropometric
ethnic
characteristics
must
be
considered
before
surgery.
The
most
common
patient
complains
and
several
clinical
cases
which
illustrate
the
procedure
used
to
refine
the
nose
with
a
closed
or
an
opened
approach
are
presented.
Variations
of
the
characteristics
of
the
nasal
bone,
the
cartilages,
the
nostrils,
and
the
tip
in
several
ethnics
groups
are
presented.
We
describe
their
specific
nasal
anatomy,
present
theirs
complains
and
descript
the
different
surgical
therapeutic
options
chosen.
A
wide
dorsum
with
or
without
a
hump,
a
large
or
globulous
tip,
an
important
alar
flaring
and
an
inter-­‐alar
width,
a
large
tip
with
thick
fibro-­‐fatty
subcutaneous
layer
which
decreases
nasal
tip
definition:
are
frequent
patient
complain.
Hump
resection,
alar
cartilage
resection,
tip
thinning,
lateral
osteotomies,
tip
enhancement
with
cartilaginous
graft,
interdomal
or
interalar
sutures
and
alar
base
resection
permit
to
refine
the
nose.
When
cartilaginous
graft
or
interdomal
sutures
are
required,
the
open
approach
can’t
be
avoided.
If
the
majority
of
rhinoplasty
indications
and
patient
complains,
especially
when
nose
thinning
is
desired,
are
treated
by
surgery,
some
indications
can
belong
to
a
medical
rhinoplasty,
especially
a
mild
hump
of
the
dorsum
or
a
multi-­‐operated
nose
with
small
imperfection
of
the
tip,
or
bony
imperfection
of
osteotomy.
Thinning
the
nose
involved
generally
treatment
of
the
tip,
the
dorsum
and
sometime
alar
rim.

15.
PRESS
Kit
–
Hong
Kong
-­‐
October
2012
IMCAS
PRESS
OFFICE
-­‐
P.B
Communication
7
Villa
des
Sablons–
92200
Neuilly
sur
Seine
-­‐
Tel
:
+
33
1
47
31
11
06
-­‐
E-­‐mail
:
pbcom@wanadoo.fr
www.imcas.com
15
Update on stem cells & lipofilling
Face, breast & body: the Regenerative Medecine
ILLOUZ
Yves
Gérard,
Plastic
Surgeon,
FRANCE
Regenerative
medecine
is
and
will
be
the
future
most
important
part
of
medecine
and
plastic
surgery
-­‐
First,
the
filling
as
a
non
invasive
procedure
will
replace
slowly
and
slowly
most
of
the
invasive
procedure
as
face
lifting,
breast
augmentation,
buttock's
augmentation....
-­‐
Adipose
Stem
cells
in
the
same
time
will
produce
a
"real"
rejunevation
of
the
skin
and
even
a
rejunevation
and
regeneration
of
disable
organs.
-­‐
The
extra
cellular
matrix
will
be
able
to
create
completely
new
organs
as
kidney,
lungs...
So,
in
a
very
near
future
regenerative
medecine
will
be
able
to
treat
almost
all
the
non
curable
diseases
with
a
minimum
of
trauma.
Patricia
Bénitah
-­‐
IMCAS
PRESS
OFFICE
Tel:
+
33
6
29
44
83
09
–
E-­‐Mail:
pbcom@wanadoo.fr
May
Lam
–
LOCAL
PRESS
OFFICE
Tel:
+
852
91
99
06
41
–
E-­‐Mail:
may@mpnetwork.hk
for
more
info,
check:
IMCAS
WEB
TV
Follow
IMCAS
on
Twitter
Find
IMCAS
on
Facebook
Join
IMCAS
on
Linked
In